CSL Paid $355 Million and Gave Up 45% of the Profits to Win a Claudin-1 Antibody
CSL and Alentis Therapeutics announced on 5 October an exclusive global agreement to co-develop and co-promote lixudebart, an antibody against exposed claudin-1 that the companies describe as potentially first-in-class. It is in the Phase 2 RENAL trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), where an interim analysis showed improved kidney function at 24 weeks, and the partners will also take it into focal segmental glomerulosclerosis and primary sclerosing cholangitis. CSL fully funds RENAL, a planned Phase 3 in AAV-RPGN and the Phase 2 trials in the other two diseases. The agreement is for lixudebart; Alentis’s two claudin-1 antibody-drug conjugates for cancer are in their own Phase 1/2 studies.
The headline understates what Alentis kept. There are no development milestones and no royalty: CSL pays $355 million now, funds every trial through Phase 3, and then splits global profits 55 to 45. That is closer to co-ownership than a licence, and it shows CSL wanted lixudebart enough to give up nearly half the economics.
- Nephrology incumbents: CSL is building around AAV. CSL Vifor already sells avacopan for AAV outside the US, and research head Bill Mezzanotte framed the deal as part of building a leading global nephrology franchise. An antibody designed to prevent and reverse organ damage would sit alongside an anti-inflammatory, in the same specialist call points.
- Fibrosis developers: claudin-1 now has a large-cap backer. Alentis chief executive Mark Pruzanski called the deal further validation of the target, and the plan spans kidney and liver, with an FDA orphan designation already granted in idiopathic pulmonary fibrosis. Single-organ fibrosis programmes now compete with one designed to cross organs.
- Signposts: the full RENAL data and the Phase 3 design. The efficacy case rests on an interim analysis in 26 patients, with no effect sizes disclosed, and a six-week liver study in 41 patients. The full RENAL readout and the endpoints CSL chooses for Phase 3 will show how much of the $355 million paid for data and how much for the target.